Compass Pathways gains on mid-stage data for experimental PTSD treatment

COMPASS Pathways

08/05/2024 14:27

** Shares of biotech firm Compass Pathways  CMPS.O  up about
2% at $8.71 premarket
    ** Company says its experimental psilocybin treatment,
COMP360, helped improve symptoms of post traumatic stress
disorder (PTSD) in patients
    ** COMP360 is a synthetic form of psilocybin, a naturally
occurring psychedelic compound that is found in certain mushroom
varieties
    ** The drug helped improve functional impairments, or
limitations in social, family or work life caused by the
disease, over 12 weeks - CMPS
    ** CMPS says the drug was well tolerated, but flags two
suicidal ideation adverse events that took place during the
study and were resolved
    ** One of the events was related to the drug and the second
event could also "possibly" be related to it, company says
    ** Data is from an open label mid-stage study testing the
safety and tolerability of the drug in 22 patients with PTSD
    ** As of last close, CMPS down 2.4% YTD

 (Reporting by Bhanvi Satija in Bengaluru)
 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))